How Recent Developments Are Shaping the Boston Scientific Investment Story

Boston Scientific's stock has seen a modest increase in its consensus analyst price target, rising slightly from $126.14 to $126.48. This minor upward adjustment reflects a balance between recent optimism around the company's earnings momentum, strategic acquisitions, and longer-term growth strategy. At the same time, there are more cautious views regarding current valuation and potential market risks. To discover how investors and analysts can keep up with the evolving story of Boston Scientific, read on for more insights and practical tips.

Stay updated as the Fair Value for Boston Scientific shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific.

What Wall Street Has Been Saying

🐂 Bullish Takeaways

Truist increased its price target to $130, noting a solid third-quarter earnings beat and accelerating Watchman growth. The firm remains confident that Boston Scientific can deliver further upside to its higher guidance. Morgan Stanley raised its target to $130 from $125. Analyst Patrick Wood made modest model updates on recent guidance and long-term targets and retained an Overweight rating. Goldman Sachs lifted its price target to $124 from $120, emphasizing Boston Scientific's revised 2025 forecasts for organic growth and earnings per share, as well as positive business mix and robust free cash flow projections. The firm continues to believe Boston Scientific is materially ahead of MedTech peers in sales and earnings potential. Barclays set a new price target at $136, highlighting the company’s "impressive" three-year outlook for organic growth of 10% and projecting "significant upside" for shares as a result of broad growth initiatives. Leerink views the recent acquisition of Nalu Medical as another strong, strategic deal and reiterates an Outperform rating, noting Boston Scientific’s continued effective execution in building its pipeline through innovation and M&A. Evercore ISI increased its target to $113 from $110, citing the company’s stronger-than-expected EP results and stating that shares rose appropriately following alleviated concerns around market share. Truist highlighted after Investor Day, sustained above-average double-digit revenue and EPS growth, as well as Boston Scientific’s best-in-class pipeline and attractive end markets, when it raised its price target to $129.

🐻 Bearish Takeaways

Erste Group downgraded the stock to Hold from Buy, arguing that sales growth in 2026 is expected to trail 2025 and that Boston Scientific shares are expensive relative to peers with limited upside from current levels. Some analysts, even as they raise targets, have flagged reservations about current valuation, the degree of upside already priced into shares, and the potential for decelerating growth rates over the next several years.

Story Continues

Overall, analyst commentary points to general confidence in Boston Scientific’s execution, product pipeline, and earnings outlook, though caution is advised regarding valuation and the pace of medium-term growth. The stock’s valuation is a recurring consideration, with some seeing ample room for further gains, while others recommend a more measured approach given current market levels.

Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives or begin writing your own Narrative!NYSE:BSX Community Fair Values as at Nov 2025

What's in the News

Truist raised its price target for Boston Scientific shares to $130 from $129 and maintained a Buy rating after a strong third quarter. The firm highlighted accelerating Watchman growth along with increased confidence in company guidance. Boston Scientific issued upbeat earnings guidance, projecting fourth quarter net sales growth of 14.5% to 16.5% and up to 20% annual growth for 2025 on a reported basis. The company also outlined targets for organic growth and earnings per share. The company hosted an Analyst and Investor Day, where leadership reviewed updated financial goals and discussed long-term growth strategies for the business.

How This Changes the Fair Value For Boston Scientific

Consensus Analyst Price Target (Fair Value): increased slightly from $126.14 to $126.48, reflecting a minimal upward adjustment. Discount Rate: rose from 7.60% to 7.89%, indicating a modest rise in the rate applied to future cash flows. Revenue Growth: moved up marginally from 11.04% to 11.05%, suggesting analysts expect growth to be maintained at high levels. Net Profit Margin: improved slightly from 19.27% to 19.34%, showing expectations for stronger profitability. Future P/E: increased modestly from 46.32x to 46.74x, signaling a minor recalibration of forward earnings multiples.

🔔 Never Miss an Update: Follow The Narrative

A Narrative is a powerful way to invest; it's the story behind the numbers. Narratives on Simply Wall St link a company's unique journey to a financial forecast and fair value, helping investors connect business developments with future growth and valuation. Easily accessible in the Community page and used by millions, Narratives help you spot buy and sell opportunities by tracking fair value versus price and stay updated dynamically as new news or earnings come in.

Head over to the Simply Wall St Community Narrative on Boston Scientific to follow:

How recent acquisitions and innovation in therapies could drive Boston Scientific’s expansion and margin growth. The expected impact of global diversification, operational efficiency, and investments in high-value technologies on long-term earnings. The major risks and catalysts that may shape fair value, such as competition, regulatory changes, and execution challenges, as forecasts and market realities evolve.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BSX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments